Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) EEG Signals ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2022

ABSTRACT

The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is challenging given the lack of objective diagnostic and monitoring tools with high sensitivity and specificity. A cornerstone in research of neurological disorders manifesting as MDi is the investigation of neurophysiological changes as potential biomarkers that could help in diagnosis, monitoring disease progression and response to therapies. Such a neuro-marker that would overcome the major disadvantages of clinical questionnaires and rating scales (such as the Unified Parkinson's disease rating scale -UPDRS, for PD, The Essential Tremor Rating Assessment Scale -TETRAS, for ET and others), including low test-retest repeatability and subjective judgment of different raters, would have real impact on disease diagnosis and choice of interventions and monitoring of effects of novel therapeutics, including disease modifying therapies. To address this, ElMindA has developed over the last decade a non-invasive, low-cost technology named Brain Network Activation (BNA), which is a new imaging approach that can detect changes in brain activity and functional connectivity. Results from proof-of concept studies on PD patients have demonstrated that: 1) PD patients exhibited a significant decrease in BNA scores relatively to healthy controls; 2) notable changes in functional network activity in correlation with different dopamine-agonist doses; 3) significant correlation between BNA score and the UPDRS). 4) BNA could also differentiate early PD from healthy controls Detailed Description Objective: The primary aim of the current project is to assess the utility of the BNA as a quantitative, objective, neurophysiological marker for diagnosis and monitoring of the above most common MDi in man. The secondary aim is to find predictive bio-types (electrophysiological fingerprint) of the above MDi and within these disorders identifying patients with high likelihood of developing: 1) psychiatric complications such as dopaminergic medication induced-impulse control disorder (ICD) for PD; 2) Depression; 3) Gait and balance Impairment; or 4) Cognitive deterioration, including (PD-MCI) or PD-dementia (PDD). The technology: BNA technology is based on non-invasive recordings of multi-channel EEG event-related potentials (ERPs), and a comprehensive multi-dimensional analysis of such recordings, aimed at understanding and visualizing the network complexity (or Brain Networks Activation patterns) of brain function. BNA takes cognitive ERPs, a direct measure of neural activity associated with cognitive functions, to a new frontier, unparalleled by EEG, QEEG or ERP alone or by any other anatomic and functional brain imaging and evaluation tools. The BNA algorithms use innovative sets of signal processing, pattern recognition and machine learning techniques to seek and map activated neural pathways while patients are engaged in a cognitive task. The resulting BNA network patterns can aid clinicians with profiling of changes in functionality and/or dysfunctionality. BNA received an FDA clearance and a CE mark approval during 2014, and is commercially available in the US, with more than 20 active clinical and research sites focusing on numerous neurological and neuropsychological disorders. More than 30,000 data sets of functional brain networks of healthy subjects have been already collected and may serve as normative data for comparison. More... »

URL

https://clinicaltrials.gov/show/NCT03269201

Related SciGraph Publications

  • 2016-12. The study of brain functional connectivity in Parkinson’s disease in TRANSLATIONAL NEURODEGENERATION
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is challenging given the lack of objective diagnostic and monitoring tools with high sensitivity and specificity. A cornerstone in research of neurological disorders manifesting as MDi is the investigation of neurophysiological changes as potential biomarkers that could help in diagnosis, monitoring disease progression and response to therapies. Such a neuro-marker that would overcome the major disadvantages of clinical questionnaires and rating scales (such as the Unified Parkinson's disease rating scale -UPDRS, for PD, The Essential Tremor Rating Assessment Scale -TETRAS, for ET and others), including low test-retest repeatability and subjective judgment of different raters, would have real impact on disease diagnosis and choice of interventions and monitoring of effects of novel therapeutics, including disease modifying therapies. To address this, ElMindA has developed over the last decade a non-invasive, low-cost technology named Brain Network Activation (BNA), which is a new imaging approach that can detect changes in brain activity and functional connectivity. Results from proof-of concept studies on PD patients have demonstrated that: 1) PD patients exhibited a significant decrease in BNA scores relatively to healthy controls; 2) notable changes in functional network activity in correlation with different dopamine-agonist doses; 3) significant correlation between BNA score and the UPDRS). 4) BNA could also differentiate early PD from healthy controls\n\nDetailed Description\nObjective: The primary aim of the current project is to assess the utility of the BNA as a quantitative, objective, neurophysiological marker for diagnosis and monitoring of the above most common MDi in man. The secondary aim is to find predictive bio-types (electrophysiological fingerprint) of the above MDi and within these disorders identifying patients with high likelihood of developing: 1) psychiatric complications such as dopaminergic medication induced-impulse control disorder (ICD) for PD; 2) Depression; 3) Gait and balance Impairment; or 4) Cognitive deterioration, including (PD-MCI) or PD-dementia (PDD). The technology: BNA technology is based on non-invasive recordings of multi-channel EEG event-related potentials (ERPs), and a comprehensive multi-dimensional analysis of such recordings, aimed at understanding and visualizing the network complexity (or Brain Networks Activation patterns) of brain function. BNA takes cognitive ERPs, a direct measure of neural activity associated with cognitive functions, to a new frontier, unparalleled by EEG, QEEG or ERP alone or by any other anatomic and functional brain imaging and evaluation tools. The BNA algorithms use innovative sets of signal processing, pattern recognition and machine learning techniques to seek and map activated neural pathways while patients are engaged in a cognitive task. The resulting BNA network patterns can aid clinicians with profiling of changes in functionality and/or dysfunctionality. BNA received an FDA clearance and a CE mark approval during 2014, and is commercially available in the US, with more than 20 active clinical and research sites focusing on numerous neurological and neuropsychological disorders. More than 30,000 data sets of functional brain networks of healthy subjects have been already collected and may serve as normative data for comparison.", 
        "endDate": "2022-09-01T00:00:00Z", 
        "id": "sg:clinicaltrial.NCT03269201", 
        "keywords": [
          "mapping", 
          "functional network", 
          "brain network", 
          "evoked response", 
          "ERP", 
          "EEG signal", 
          "movement disorder", 
          "diagnosis", 
          "management", 
          "Parkinson Disease", 
          "Parkinson", 
          "dystonia", 
          "essential tremor", 
          "Normal Pressure Hydrocephalus", 
          "tool", 
          "high sensitivity", 
          "Sensitivity and Specificity", 
          "cornerstone", 
          "Nervous System Disease", 
          "Metered Dose Inhaler", 
          "neurophysiological change", 
          "potential biomarkers", 
          "disease progression", 
          "therapy", 
          "marker", 
          "major disadvantage", 
          "questionnaire", 
          "rating scale", 
          "Parkinson's", 
          "test-retest", 
          "subjective judgment", 
          "raters", 
          "real impact", 
          "disease diagnosis", 
          "intervention", 
          "novel therapeutic", 
          "disease", 
          "last decade", 
          "low-cost technology", 
          "imaging approach", 
          "brain activity", 
          "functional connectivity", 
          "proof-of-concept study", 
          "Parkinson's disease patient", 
          "significant decrease", 
          "healthy control", 
          "correlation", 
          "dopamine agonist", 
          "significant correlation", 
          "early Parkinson's disease", 
          "detailed description", 
          "primary aim", 
          "current project", 
          "utility", 
          "human", 
          "secondary aim", 
          "bio", 
          "disorder", 
          "patient", 
          "high likelihood", 
          "psychiatric complication", 
          "impulse control disorder", 
          "depression", 
          "gait", 
          "balance impairment", 
          "cognitive deterioration", 
          "Parkinson's disease dementia", 
          "technology", 
          "recording", 
          "Evoked Potential", 
          "dimensional analysis", 
          "complexity", 
          "pattern", 
          "brain function", 
          "event related potential", 
          "direct measure", 
          "neural activity", 
          "cognitive function", 
          "Electroencephalography", 
          "imaging", 
          "evaluation tool", 
          "innovative set", 
          "signal processing", 
          "pattern recognition", 
          "machine", 
          "technique", 
          "neural pathway", 
          "cognitive task", 
          "clinician", 
          "profiling", 
          "functionality", 
          "FDA clearance", 
          "CE", 
          "approval", 
          "US", 
          "research site", 
          "Dataset", 
          "functional brain network", 
          "healthy subject", 
          "normative data", 
          "comparison"
        ], 
        "name": "Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) EEG Signals in Patients With Movement Disorders", 
        "sameAs": [
          "https://app.dimensions.ai/details/clinical_trial/NCT03269201"
        ], 
        "sdDataset": "clinical_trials", 
        "sdDatePublished": "2019-03-07T15:27", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "file:///pack/app/us_ct_data_00025.json", 
        "sponsor": [
          {
            "id": "https://www.grid.ac/institutes/grid.413795.d", 
            "type": "Organization"
          }
        ], 
        "startDate": "2017-09-01T00:00:00Z", 
        "subjectOf": [
          {
            "id": "sg:pub.10.1186/s40035-016-0066-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006274936", 
              "https://doi.org/10.1186/s40035-016-0066-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40035-016-0066-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006274936", 
              "https://doi.org/10.1186/s40035-016-0066-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12031-014-0250-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016583919", 
              "https://doi.org/10.1007/s12031-014-0250-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.neuroimage.2013.11.020", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035131634"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1371/journal.pone.0141815", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040740203"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ejp.716", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052318487"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "type": "MedicalStudy", 
        "url": "https://clinicaltrials.gov/show/NCT03269201"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03269201'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03269201'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03269201'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03269201'


     

    This table displays all metadata directly associated to this object as RDF triples.

    137 TRIPLES      16 PREDICATES      121 URIs      110 LITERALS      1 BLANK NODES

    Subject Predicate Object
    1 sg:clinicaltrial.NCT03269201 schema:about anzsrc-for:3120
    2 schema:description The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is challenging given the lack of objective diagnostic and monitoring tools with high sensitivity and specificity. A cornerstone in research of neurological disorders manifesting as MDi is the investigation of neurophysiological changes as potential biomarkers that could help in diagnosis, monitoring disease progression and response to therapies. Such a neuro-marker that would overcome the major disadvantages of clinical questionnaires and rating scales (such as the Unified Parkinson's disease rating scale -UPDRS, for PD, The Essential Tremor Rating Assessment Scale -TETRAS, for ET and others), including low test-retest repeatability and subjective judgment of different raters, would have real impact on disease diagnosis and choice of interventions and monitoring of effects of novel therapeutics, including disease modifying therapies. To address this, ElMindA has developed over the last decade a non-invasive, low-cost technology named Brain Network Activation (BNA), which is a new imaging approach that can detect changes in brain activity and functional connectivity. Results from proof-of concept studies on PD patients have demonstrated that: 1) PD patients exhibited a significant decrease in BNA scores relatively to healthy controls; 2) notable changes in functional network activity in correlation with different dopamine-agonist doses; 3) significant correlation between BNA score and the UPDRS). 4) BNA could also differentiate early PD from healthy controls Detailed Description Objective: The primary aim of the current project is to assess the utility of the BNA as a quantitative, objective, neurophysiological marker for diagnosis and monitoring of the above most common MDi in man. The secondary aim is to find predictive bio-types (electrophysiological fingerprint) of the above MDi and within these disorders identifying patients with high likelihood of developing: 1) psychiatric complications such as dopaminergic medication induced-impulse control disorder (ICD) for PD; 2) Depression; 3) Gait and balance Impairment; or 4) Cognitive deterioration, including (PD-MCI) or PD-dementia (PDD). The technology: BNA technology is based on non-invasive recordings of multi-channel EEG event-related potentials (ERPs), and a comprehensive multi-dimensional analysis of such recordings, aimed at understanding and visualizing the network complexity (or Brain Networks Activation patterns) of brain function. BNA takes cognitive ERPs, a direct measure of neural activity associated with cognitive functions, to a new frontier, unparalleled by EEG, QEEG or ERP alone or by any other anatomic and functional brain imaging and evaluation tools. The BNA algorithms use innovative sets of signal processing, pattern recognition and machine learning techniques to seek and map activated neural pathways while patients are engaged in a cognitive task. The resulting BNA network patterns can aid clinicians with profiling of changes in functionality and/or dysfunctionality. BNA received an FDA clearance and a CE mark approval during 2014, and is commercially available in the US, with more than 20 active clinical and research sites focusing on numerous neurological and neuropsychological disorders. More than 30,000 data sets of functional brain networks of healthy subjects have been already collected and may serve as normative data for comparison.
    3 schema:endDate 2022-09-01T00:00:00Z
    4 schema:keywords CE
    5 Dataset
    6 EEG signal
    7 ERP
    8 Electroencephalography
    9 Evoked Potential
    10 FDA clearance
    11 Metered Dose Inhaler
    12 Nervous System Disease
    13 Normal Pressure Hydrocephalus
    14 Parkinson
    15 Parkinson Disease
    16 Parkinson's
    17 Parkinson's disease dementia
    18 Parkinson's disease patient
    19 Sensitivity and Specificity
    20 US
    21 approval
    22 balance impairment
    23 bio
    24 brain activity
    25 brain function
    26 brain network
    27 clinician
    28 cognitive deterioration
    29 cognitive function
    30 cognitive task
    31 comparison
    32 complexity
    33 cornerstone
    34 correlation
    35 current project
    36 depression
    37 detailed description
    38 diagnosis
    39 dimensional analysis
    40 direct measure
    41 disease
    42 disease diagnosis
    43 disease progression
    44 disorder
    45 dopamine agonist
    46 dystonia
    47 early Parkinson's disease
    48 essential tremor
    49 evaluation tool
    50 event related potential
    51 evoked response
    52 functional brain network
    53 functional connectivity
    54 functional network
    55 functionality
    56 gait
    57 healthy control
    58 healthy subject
    59 high likelihood
    60 high sensitivity
    61 human
    62 imaging
    63 imaging approach
    64 impulse control disorder
    65 innovative set
    66 intervention
    67 last decade
    68 low-cost technology
    69 machine
    70 major disadvantage
    71 management
    72 mapping
    73 marker
    74 movement disorder
    75 neural activity
    76 neural pathway
    77 neurophysiological change
    78 normative data
    79 novel therapeutic
    80 patient
    81 pattern
    82 pattern recognition
    83 potential biomarkers
    84 primary aim
    85 profiling
    86 proof-of-concept study
    87 psychiatric complication
    88 questionnaire
    89 raters
    90 rating scale
    91 real impact
    92 recording
    93 research site
    94 secondary aim
    95 signal processing
    96 significant correlation
    97 significant decrease
    98 subjective judgment
    99 technique
    100 technology
    101 test-retest
    102 therapy
    103 tool
    104 utility
    105 schema:name Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) EEG Signals in Patients With Movement Disorders
    106 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03269201
    107 schema:sdDatePublished 2019-03-07T15:27
    108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    109 schema:sdPublisher N351214d864434cffb10bb7cfd357bf57
    110 schema:sponsor https://www.grid.ac/institutes/grid.413795.d
    111 schema:startDate 2017-09-01T00:00:00Z
    112 schema:subjectOf sg:pub.10.1007/s12031-014-0250-6
    113 sg:pub.10.1186/s40035-016-0066-0
    114 https://doi.org/10.1002/ejp.716
    115 https://doi.org/10.1016/j.neuroimage.2013.11.020
    116 https://doi.org/10.1371/journal.pone.0141815
    117 schema:url https://clinicaltrials.gov/show/NCT03269201
    118 sgo:license sg:explorer/license/
    119 sgo:sdDataset clinical_trials
    120 rdf:type schema:MedicalStudy
    121 N351214d864434cffb10bb7cfd357bf57 schema:name Springer Nature - SN SciGraph project
    122 rdf:type schema:Organization
    123 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
    124 rdf:type schema:DefinedTerm
    125 sg:pub.10.1007/s12031-014-0250-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016583919
    126 https://doi.org/10.1007/s12031-014-0250-6
    127 rdf:type schema:CreativeWork
    128 sg:pub.10.1186/s40035-016-0066-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006274936
    129 https://doi.org/10.1186/s40035-016-0066-0
    130 rdf:type schema:CreativeWork
    131 https://doi.org/10.1002/ejp.716 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052318487
    132 rdf:type schema:CreativeWork
    133 https://doi.org/10.1016/j.neuroimage.2013.11.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035131634
    134 rdf:type schema:CreativeWork
    135 https://doi.org/10.1371/journal.pone.0141815 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040740203
    136 rdf:type schema:CreativeWork
    137 https://www.grid.ac/institutes/grid.413795.d schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...